Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine effect on ciprofol ED50 for painless gastroscopy anesthesia induction
ChiCTR2600133502Phase 4Not yet recruiting
- Sponsor
- Yancheng First People's Hospital
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of oliceridine, ciprofol and sufentanil (3 arms), sponsored by Yancheng First People's Hospital. Primary endpoint: 50% effective dose (ED50). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
oliceridineciprofolsufentanil
Beyond the preview
Go deeper on ChiCTR2600133502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133502.